CervoMed Inc. (CRVO)
D
Pipeline Grade
Financial Position (from SEC Filings)
$10.5M
Cash & Equivalents
$8.0M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$48M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase2 Readout | — |
| 2026-09-30 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06987643 | A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke | PHASE2 | Active Not Recruiting | 90 |
| NCT07033481 | Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia | PHASE2 | Active Not Recruiting | 20 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-07-09 | 8-K | CervoMed Inc. (CRVO) (CIK 0001053691) - EXHIBIT 99.1 | EDGAR |
| 2026-06-22 | 8-K | CervoMed Inc. (CRVO) (CIK 0001053691) - EXHIBIT 99.1 | EDGAR |
| 2026-06-22 | 8-K | CervoMed Inc. (CRVO) (CIK 0001053691) - EXHIBIT 99.1 | EDGAR |
| 2026-06-10 | 8-K | CervoMed Inc. (CRVO) (CIK 0001053691) - EXHIBIT 99.1 | EDGAR |